McKesson Corporation (MCK)

FairStock Score: 55/100 — STEADY

Key Financials

Strengths

• Dominant market position in U.S. pharmaceutical distribution with scale-based competitive moat
• Exceptional free cash flow generation of $9.2B despite thin 1.12% margins
• Piotroski F-Score of 8/9 demonstrates strong underlying financial quality and management execution
• Essential business benefiting from aging demographics and rising medication utilization
• Low beta of 0.35 provides portfolio stability and defensive characteristics

Concerns

• Valuation is stretched at 25.57 P/E and 64.83 EV/EBITDA for a mature, low-growth distributor
• Anemic 4.33% ROCE suggests capital is not deployed efficiently despite scale advantages
• Thin 1.12% net margins leave minimal pricing power against suppliers and customers
• Altman Z-Score of 2.38 indicates financial stress levels requiring monitoring

AI Analysis

McKesson presents a classic case of a mature, essential business trading at a premium valuation. As one of America's largest pharmaceutical distributors, it operates a natural monopoly-like moat—pharmaceutical supply chains require scale, trust, and regulatory compliance that smaller competitors cannot replicate. The company's 43,000-employee operation moves over $106 billion in quarterly revenue with remarkable efficiency. Its 1.12% net margin reflects the razor-thin nature of distribution, yet the business generates exceptional free cash flow of $9.2 billion annually. This is predictable, recurring revenue from an aging population requiring more medications. However, I'm troubled by the valuation. At 25.57 P/E and a 64.83 EV/EBITDA multiple, McKesson commands a steep price. The 0.9% free cash flow yield is mediocre—I'd expect 3-4% for a mature distributor. The Piotroski F-Score of 8/9 is excellent, showing strong financial health, but the Altman Z-Score of 2.38 suggests moderate distress territory. What concerns me most is the 4.33% ROCE—barely acceptable for a capital-intensive business. This is not a compounder; it's a mature cash generator that must justify its $116.3B valuation through consistent execution and industry tailwinds, not growth. The fair value score of 38/100 confirms my skepticism. I'd want to buy this at $600-700, not $942.

Bull Case

McKesson's defensive moat and $9.2B annual free cash flow support long-term value creation, particularly as healthcare spending accelerates with an aging population. Specialty pharmaceuticals and RxTS technology solutions offer higher-margin growth vectors that could improve overall returns on capital.

Bear Case

Pharmaceutical distribution is consolidating into fewer hands with commoditizing economics, while price pressure from healthcare reform and customer consolidation will continue squeezing margins. The stock may struggle to justify its current valuation if free cash flow growth remains single-digit.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer